Navigation Links
BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012

LYNBROOK, N.Y., Aug. 29, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that Thomas L. Wegman, President of BioSpecifics, will present at the Stifel Nicolaus Weisel Healthcare Conferences 2012 at 9:45 am EDT on Wednesday, September 5, 2012 in Boston, MA.

The live webcast of this presentation may be accessed under "Calendar of Events" in the Investor Relations section of BioSpecifics' website at or at the link A replay of the webcast will also be available on the Company's website following the presentation.

About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase (XIAFLEX®) for twelve clinical indications. Currently, XIAFLEX is marketed in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is also in clinical development for the treatment of several additional promising indications. Auxilium has reported positive top-line results from two recently completed Phase III clinical trials for Peyronie's disease and is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib clinical trials, respectively. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in Phase II clinical trials.  Auxilium has entered into three strategic partnerships for development and commercialization outside the U.S. of injectable collagenase for Dupuytren's contracture and Peyronie's disease. Pfizer Inc. has rights in Europe and Eurasia and injectable collagenase is currently marketed as XIAPEX® for Dupuytren's contracture in select European countries. Asahi Kasei Pharma Corporation has rights in Japan and Actelion Pharmaceuticals Canada Inc. has rights in Canada, Australia, Brazil and Mexico. For more information, please visit


SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
2. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
3. Antifungal Drugs: Technologies and Global Markets
4. Cleveland Clinics 2012 Medical Innovation Summit Highlights Orthopaedic Technologies
5. Breast Cancer Diagnostic and Drug Technologies: Global Markets
6. ARAMARK Healthcare Technologies Taps Robert Steele to Lead ReMedPar
7. Montmed to Participate in 2013 Advanced Technologies and Treatments for Diabetes Conference
8. U.S. Navy Awards Multi-Million Dollar Contract to Innovation for Pharmacy Automation Technologies
9. Technologies Impacting the Future of Healthcare
10. ECRI Institute Helps Hospitals Design Spaces for Current and Future Technologies
11. Patient Safety Technologies Reports Second Quarter 2012 Results
Post Your Comments:
(Date:11/24/2015)... , November 24, 2015 F1000Workspace ... for scientists - since it was launched just six months ... reference management and authoring platform for scientists - since it ... million references have been loaded on to F1000Workspace ... scientists - since it was launched just six months ago. ...
(Date:11/24/2015)... iRhythm Technologies, Inc. , a leading digital health care solutions company ... in the 27th Annual Piper Jaffray Healthcare Conference at The New ... . Kevin King , Chief Executive Officer of iRhythm, is ... --> --> About iRhythm ... . --> iRhythm is a privately held digital healthcare ...
(Date:11/24/2015)... The uptake of recently approved and pipeline premium ... of market growth to 2021, says GBI Research ... products for Type 1 Diabetes Mellitus (T1DM), will be a key driver ... . --> The uptake of recently approved and pipeline ... driver of market growth to 2021, says GBI Research ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 2015 , ... Eric C. Seidel, DMD and Stephanie DeFilippo, ... revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology uses light energy ... dentist in Gettysburg, PA . From routine visits to cosmetic treatments, laser dentistry ...
(Date:11/24/2015)... ... , ... Charitable giving is at its peak during the holidays. In ... of the year totalling over $358 billion in 2014. With more than 1.5 ... those individuals who want to “give back” during the holidays. , “With so many ...
(Date:11/24/2015)... ... ... DMG Productions announced that they will feature Aphria, Inc., in an upcoming episode ... and show times TBA. , Aphria, Inc., is a publicly traded company incorporated under ... medical marijuana pursuant to the Marijuana for Medical Purposes Regulations (the “MMPR”). , Aphria ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the organization will waive paid entry and parking fees at several of their ... Monument Mountain in Great Barrington in support of REI’s Black Friday #OptOutside Campaign. ...
(Date:11/24/2015)... N.J. (PRWEB) , ... November 24, 2015 , ... ... will gather to share their knowledge and experiences at a live taping of ... the Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown ...
Breaking Medicine News(10 mins):